Bismuth
PreclinicalSmall molecule
Bismuth is one of 44 small molecule programs targeting Toxicity. It is currently in Preclinical.
2
Indications
25
Total Trials
3
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
223 competitors in Toxicity
#DrugCompanyPhaseTrials
1Erbitux
IImclone
Phase 3
Coly-Mycin M
PParkedale
Phase 3
Intelence
WWim Janssens
Phase 3
Curcumin
Merck & Co.Phase 3
Trizivir
GSKPhase 3
Cysteine Hydrochloride
NovartisPreclinical
Tenofovir/emtricitabine/rilpivirine
MMahidol University
Phase 3
Colistin Sulfomethate
MMahidol University
Phase 3
Imfinzi
AstraZenecaPreclinical
Cellcept
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori Eradication7 trials
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
Completed·—·Phase 4·NCT00841854·199 enrolled
Show 4 more trials
Helicobacter3 trials
Helicobacter Pylori2 trials
7 more indications
Efficacy and Safety2 trials
Bismuth Quadruple Therapy2 trials
Randomized Controlled Trial1 trial
Oral1 trial
Toxicity1 trial
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
Completed·—·N/A·NCT00892502·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bismuth. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details